Gilead Sciences (GILD) Work In Process (2009 - 2015)
Gilead Sciences' (GILD) quarterly Work In Process came in at $542.0 million in Q4 2015, up 8.4% YoY from $500.0 million in Q4 2014, and up 8.4% on a QoQ basis from $500.0 million in Q4 2014.
Gilead Sciences (GILD) Work In Process (2009 - 2015) Analysis & Trends
Gilead Sciences (GILD) has 7 years of Work In Process data on file, last reported at $542.0 million in Q4 2015.
- Quarterly Work In Process rose 8.4% year-over-year to $542.0 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $542.0 million (up 8.4% YoY) and the FY2015 annual result came in at $542.0 million, up 8.4% from the prior year.
- Work In Process improved to $542.0 million in Q4 2015, from $500.0 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $563.9 million in Q2 2014 to a low of $175.5 million in Q3 2011.
- A 5-year average of $398.7 million and a median of $412.9 million in 2013 frame the typical range for Work In Process.
- Annual changes were most pronounced in 2011 — Work In Process plunged 55.28% — and 2014, when it gained 21.08%.
- Tracing GILD's Work In Process over 5 years: stood at $466.5 million in 2011, then declined by 23.15% to $358.5 million in 2012, then climbed by 15.18% to $412.9 million in 2013, then grew by 21.08% to $500.0 million in 2014, then grew by 8.4% to $542.0 million in 2015.
- The last three Work In Process figures came in at $542.0 million (Q4 2015), $500.0 million (Q4 2014), and $563.9 million (Q2 2014), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.23 Bn | 630.47 Bn | 17.26 Bn |
| 2 | AbbVie | 469.32 Bn | 462.76 Bn | 12.70 Bn |
| 3 | Merck | 378.85 Bn | 371.71 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.78 Bn | 295.09 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.59 Bn | 252.69 Bn | 12.86 Bn |
| 6 | Amgen | 236.50 Bn | 222.51 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 182.49 Bn | 179.31 Bn | 6.22 Bn |
| 8 | Pfizer | 161.62 Bn | 149.92 Bn | 10.94 Bn |
| 9 | Gsk | 105.56 Bn | 101.39 Bn | 8.24 Bn |
| 10 | Sanofi | 55.10 Bn | 47.72 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 542.00 Mn |
| Dec 31, 2014 | 500.00 Mn |
| Jun 30, 2014 | 563.88 Mn |
| Dec 31, 2013 | 412.95 Mn |
| Dec 31, 2012 | 358.53 Mn |
| Dec 31, 2011 | 466.50 Mn |
| Sep 30, 2011 | 175.55 Mn |
| Jun 30, 2011 | 271.64 Mn |
| Mar 31, 2011 | 296.87 Mn |
| Dec 31, 2010 | 454.65 Mn |
| Sep 30, 2010 | 392.54 Mn |
| Dec 31, 2009 | 392.04 Mn |